SmartTRAK interviews Advanced Oxygen Therapy Inc CEO and President Dr. Mike Griffiths to discuss how durable healing can improve health equality

Oxygen-based therapies have been used on chronic wounds for many years. In a recent article on the 2023 Oxygen and Energy Market, SmartTRAK expressed the view that the Topical Oxygen Therapy Market will grow at a significant rate and that Advanced Oxygen Therapy Inc* is likely to be the biggest driver of that growth. The Company has established a solid evidence base for its TWO2* system, a Topical Wound Oxygen therapy system which applies cyclical pressurized directly to a patient’s wound at home or in a healthcare facility. SmartTRAK talked with the company Medical Director, President and CEO, Dr. Mike Griffiths, about the journey that the company has been on so far, how durable healing and patient-led home care can reduce health inequalities and why the company has recently entered the Negative Pressure Wound Therapy (NPWT) Market.

To find out more about Advanced Oxygen Therapy Inc, click on the following video to listen to the recorded interview (27:56 min). A complete transcript of the interview is available here. For more details, interview topics by timecode are provided below.

With many of the “hard yards” already run, SmartTRAK believes that 2023 could be a promising year for the Oxygen and Energy segments of the Advanced Wound Care Market.

SmartTRAK estimates the 2021 WW Oxygen and Energy Market at just over $50.0MM. While this is not an insignificant amount, it trails far behind other Advanced Wound Care markets such as Negative Pressure Wound Therapy (NPWT) and Biologics. Last year, however, showed signs that clinicians are starting to realize the potential of these technologies. Here SmartTRAK looks at how some of the existing players in the markets for oxygen and energy therapies may show increased success in 2023 and why some of the leading wound care companies may soon be taking their first steps into these markets.

Among the many topics covered in this article are:

SmartTRAK highlights novel diagnostic devices for pressure ulcer (PU) prevention and interviews PU Sensor’s CEO Johannes Walfidsson at EPUAP 2022

According to SmartTRAK incidence and prevalence data*, there were over 10 million pressure ulcers in Europe in 2021, with four million being stage III to IV. This means that pressure ulcers account for around two-thirds of the total number of chronic wounds on the continent and almost half of the hard-to-heal wounds. Given these eye-opening statistics, it would be understandable to expect that the first European Pressure Ulcer Advisory Panel (EPUAP) Meeting in three years would indicate growing engagement in this area, both clinically and commercially. Unfortunately, on the evidence of the event in Prague, this wasn’t the case, with delegate numbers declining from previous years and a sparse exhibition hall missing many of the prominent wound care players. This begs the question; why isn’t there a greater focus on pressure ulcers and prevention? (Click to listen to SmartTRAK's interview with PU Sensor's CEO Johannes Walfidsson, "Advancing Risk Assessment for Pressure Ulcers." You can also download a complete transcript of the interview here)

Could biosensors and smart dressings be the final frontier in wound diagnostics? SmartTRAK explores the current progress of this market and how it could develop.

It has been 15 years since the World Union of Wound Healing Societies’ Initiative published a consensus document entitled “Diagnostics and Wounds.” Since then, the clinical practice around assessing and diagnosing wounds has not evolved at the same rate as that of treatments. At the same time, the need for improved wound diagnostics has never been greater given burgeoning chronic wound numbers and the continued shift of wound care services to the outpatient setting.

Could the next area of development be that of biosensors and smart dressings? SmartTRAK believes there is increasing evidence that this could be the case. In this article, we explore the developments that are taking place, how the identification of infection biomarkers may be lucrative and ways the market may change in the coming years.

Among the many topics discussed in this article are:

Increased wound prevalence meets new software and solutions at WCT 2022.

There was a positive energy in the room at the 5^th Wound Care Today (WCT) conference as industry and clinicians came together in Milton Keynes. COVID-19 infection rates remain high in the UK but this is not being reflected in hospitalizations or deaths, leading to a national determination to move forward without restrictions. The pandemic has, however, shaped the priorities of those present and in a range of discussions. SmartTRAK encountered a commercial eagerness to make up for lost time and a looming burden of chronic wounds.

The SmartTRAK team will be attending the upcoming European Wound Management Association (EWMA) event May 23-25 in Paris. We would love to schedule some time to meet and hear your perspectives and views and discuss how SmartTRAK can help you make more informed strategic business decisions.